253 related articles for article (PubMed ID: 15879128)
21. A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis.
Lewēn S; Zhou H; Hu HD; Cheng T; Markowitz D; Reisfeld RA; Xiang R; Luo Y
Cancer Immunol Immunother; 2008 Apr; 57(4):507-15. PubMed ID: 17786443
[TBL] [Abstract][Full Text] [Related]
22. Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development.
Ma Y; Xiang D; Sun J; Ding C; Liu M; Hu X; Li G; Kloecker G; Zhang HG; Yan J
J Immunol; 2013 Jun; 190(11):5588-99. PubMed ID: 23630363
[TBL] [Abstract][Full Text] [Related]
23. MAGE-1/Heat shock protein 70/MAGE-3 fusion protein vaccine in nanoemulsion enhances cellular and humoral immune responses to MAGE-1 or MAGE-3 in vivo.
Ge W; Sui YF; Wu DC; Sun YJ; Chen GS; Li ZS; Si SY; Hu PZ; Huang Y; Zhang XM
Cancer Immunol Immunother; 2006 Jul; 55(7):841-9. PubMed ID: 16155756
[No Abstract] [Full Text] [Related]
24. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells.
Johnson LE; Frye TP; Chinnasamy N; Chinnasamy D; McNeel DG
Cancer Immunol Immunother; 2007 Jun; 56(6):885-95. PubMed ID: 17102977
[TBL] [Abstract][Full Text] [Related]
25. Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation.
Hobo W; Novobrantseva TI; Fredrix H; Wong J; Milstein S; Epstein-Barash H; Liu J; Schaap N; van der Voort R; Dolstra H
Cancer Immunol Immunother; 2013 Feb; 62(2):285-97. PubMed ID: 22903385
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of RL male 1 tumor growth in BALB/c mice by introduction of the RLakt gene coding for antigen recognized by cytotoxic T-lymphocytes and the GM-CSF gene by in vivo electroporation.
Tanaka M; Yamada M; Ono T; Noguchi Y; Uenaka A; Ota S; Hata H; Harada M; Tanimoto M; Nakayama E
Cancer Sci; 2004 Feb; 95(2):154-9. PubMed ID: 14965366
[TBL] [Abstract][Full Text] [Related]
27. Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins.
Pavlenko M; Roos AK; Leder C; Hansson LO; Kiessling R; Levitskaya E; Pisa P
Cancer Immunol Immunother; 2004 Dec; 53(12):1085-92. PubMed ID: 15696608
[TBL] [Abstract][Full Text] [Related]
28. Prime-Boost Vaccine Regimen for SjTPI and SjC23 Schistosome Vaccines, Increases Efficacy in Water Buffalo in a Field Trial in China.
Da'Dara AA; Li C; Yu X; Zheng M; Zhou J; Shollenberger LM; Li YS; Harn DA
Front Immunol; 2019; 10():284. PubMed ID: 30842779
[TBL] [Abstract][Full Text] [Related]
29. Topoisomerase II alpha as a universal tumor antigen: antitumor immunity in murine tumor models and H-2K(b)-restricted T cell epitope.
Park JS; Kim HS; Park MY; Kim CH; Chung YJ; Hong YK; Kim TG
Cancer Immunol Immunother; 2010 May; 59(5):747-57. PubMed ID: 19936747
[TBL] [Abstract][Full Text] [Related]
30. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated.
Harrop R; Ryan MG; Myers KA; Redchenko I; Kingsman SM; Carroll MW
Cancer Immunol Immunother; 2006 Sep; 55(9):1081-90. PubMed ID: 16311730
[TBL] [Abstract][Full Text] [Related]
31. Construction of a DNA vaccine encoding Flk-1 extracellular domain and C3d fusion gene and investigation of its suppressing effect on tumor growth.
Liang PH; Zhang KQ; Xu GL; Li YF; Wang LF; Nie ZL; Ye J; Wu G; Ge CG; Jin FS
Cancer Immunol Immunother; 2010 Jan; 59(1):93-101. PubMed ID: 19543726
[TBL] [Abstract][Full Text] [Related]
32. Effective immunotherapy of cancer by DNA vaccination.
Park JH; Kim CJ; Lee JH; Shin SH; Chung GH; Jang YS
Mol Cells; 1999 Aug; 9(4):384-91. PubMed ID: 10515601
[TBL] [Abstract][Full Text] [Related]
33. Transdermal microarrayed electroporation for enhanced cancer immunotherapy based on DNA vaccination.
Wang Y; Qu J; Xiong C; Chen B; Xie K; Wang M; Liu Z; Yue Z; Liang Z; Wang F; Zhang T; Zhu G; Kuang YB; Shi P
Proc Natl Acad Sci U S A; 2024 Jun; 121(25):e2322264121. PubMed ID: 38865265
[TBL] [Abstract][Full Text] [Related]
34. DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice.
Mkrtichyan M; Ghochikyan A; Loukinov D; Davtyan H; Ichim TE; Cribbs DH; Lobanenkov VV; Agadjanyan MG
Gene Ther; 2008 Jan; 15(1):61-4. PubMed ID: 17972923
[TBL] [Abstract][Full Text] [Related]
35. Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing alpha(1,3)galactosyl epitopes.
Rossi GR; Unfer RC; Seregina T; Link CJ
Cancer Immunol Immunother; 2005 Oct; 54(10):999-1009. PubMed ID: 15889257
[TBL] [Abstract][Full Text] [Related]
36. The translocation motif of hepatitis B virus improves protein vaccination.
Bleifuss E; Kammertoens T; Hutloff A; Quarcoo D; Dorner M; Straub P; Uckert W; Hildt E
Cell Mol Life Sci; 2006 Mar; 63(5):627-35. PubMed ID: 16482397
[TBL] [Abstract][Full Text] [Related]
37. Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines.
Mander A; Chowdhury F; Low L; Ottensmeier CH
Cancer Immunol Immunother; 2009 May; 58(5):789-800. PubMed ID: 19066888
[TBL] [Abstract][Full Text] [Related]
38. Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens.
Cho H; Binder J; Weeratna R; Dermyer M; Dai S; Boccia A; Li W; Li S; Jooss K; Merson J; Hollingsworth RE
Cancer Immunol Immunother; 2023 Feb; 72(2):287-300. PubMed ID: 35829790
[TBL] [Abstract][Full Text] [Related]
39. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects.
Llopiz D; Dotor J; Zabaleta A; Lasarte JJ; Prieto J; Borrás-Cuesta F; Sarobe P
Cancer Immunol Immunother; 2008 Jan; 57(1):19-29. PubMed ID: 17564702
[TBL] [Abstract][Full Text] [Related]
40. The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting.
Sui H; Bai Y; Wang K; Li X; Song C; Fu F; Zhang Y; Li L
Cancer Immunol Immunother; 2010 Jul; 59(7):989-99. PubMed ID: 20130861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
